Inventiva S.A.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Inventiva S.A. (Euronext Paris and Nasdaq: IVA) is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies targeting nuclear receptors, transcription factors, and epigenetic modulation for patients with significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. The company develops its lead product candidate lanifibranor, a pan-peroxisome proliferator-activated receptor (PPAR) agonist that induces anti-fibrotic, anti-inflammatory, and beneficial metabolic changes, currently in the pivotal Phase III NATiV3 clinical trial for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH); its second clinical-stage asset odiparcil, an orally available small molecule that modifies glycosaminoglycan synthesis for excretion in urine rather than cellular accumulation, targeted at mucopolysaccharidoses (MPS) including MPS VI, with clinical efforts suspended to prioritize lanifibranor while reviewing further development options; and earlier-stage preclinical programs including a Hippo signaling pathway candidate for oncology indications such as non-small cell lung cancer. Inventiva maintains partnerships including licensing and collaboration agreements with Sino Biopharm and Hepalys Pharma, Inc., as well as historical collaborations with AbbVie and Boehringer Ingelheim. Founded in 2011 and headquartered in Daix, France, the company operates a wholly-owned research and development facility with a proprietary library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, and employs a scientific team of around 90 experts in biology, medicinal chemistry, pharmacokinetics, pharmacology, and clinical development; it serves target markets in the United States, Europe, and Asia through its clinical programs and partnerships. In recent developments, Inventiva completed the first tranche of a multi-tranche equity financing of up to €348 million announced on October 14, 2024, securing €21.4 million in December 2024 through the issuance of new ordinary shares and pre-funded warrants, with proceeds primarily allocated to advance the NATiV3 trial—fully recruited with completion expected in the first half of 2025—and potential new drug application submission; the company appointed Mark Pruzanski as Chairman of the Board of Directors and Srinivas Akkaraju as a new board member in December 2024, separating the roles of Chairman and Chief Executive Officer; and received a $10 million milestone payment under an amended licensing agreement with Chia Tai Tianqing Pharmaceutical (CTTQ). As of late 2025, Inventiva reports cash and cash equivalents of €97.6 million plus €24.7 million in short-term investments, supporting operations into mid-2025 amid intensified trial recruitment.
Results of the Votes of the Combined Shareholders' General Meeting of June 30, 2026
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)
Claret Capital Partners participates in €130m financing for Inventiva
Claret Capital Partners participates in €130m financing for Inventiva
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development
Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround
Combined General Meeting of June 30, 2026 - Availability of the Preparatory Documents
Inventiva Announces Trading Resumption of its Ordinary Shares on Euronext Paris
Inventiva Announces a Comprehensive Capital Structure Optimization including Debt and Equity Financing in Advance of the Anticipated Phase 3 Readout
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Inventiva annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
Inventiva Reports 2026 First Quarter Financial Information¹
Inventiva to Present at 2026 Jefferies Global Healthcare Conference
Inventiva's Speculative Upside Through MASH Is Promising
Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026
Inventiva to Present Abstracts at the EASL Congress 2026
Inventiva to Present Abstracts at the EASL Congress 2026
eGain Launches AI Agent IVA to Deliver Accurate, Conversational Customer Service